Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Drugmakers discover tardive dyskinesia. And they profit in it.

Martha Rosenberg
Meds
November 30, 2019
Share
Tweet
Share

Before direct-to-consumer ads, physicians tried to reassure patients they were probably fine. Today, drug ads and online symptom checkers do just the opposite. The most insidious are “unbranded” ads that scare people about a disease without mentioning the drug they are trying to sell. Notable unbranded disease campaigns sell the obscure exocrine pancreatic insufficiency, shift work sleep disorder, and non-24-hour, sleep-wake disorder. Unbranded advertising is designed to appear like a public health message from the CDC, and some even run free on TV and radio as “public service announcements.”

The latest unbranded disease campaign is for tardive dyskinesia (TD), a constellation of involuntary movements, often permanent, associated with neuroleptic/antipsychotic drugs. Unlike non-24-hour sleep-wake disorder and the like, TD is a widespread, consequential condition adding to the stigma endured by people with severe psychiatric conditions. It has become more common, even among the young, as second general antipsychotics (SGA) are marketed for nonpsychotic conditions like autism, bipolar disorder, conduct disorders, ADHD, anxiety, and depression. SGAs were largely approved on their putative lower risk of causing TD compared to first-generation antipsychotics (FGA), but clinicians are now seeing the same side effect. Are the drugs even atypical some are asking? Were approvals too hasty?

While tetrabenazine has been used in TD treatment, its suicidal side effects have limited its usefulness.

Two years ago, the FDA approved valbenazine (Ingrezza) sold by Neurocrine Biosciences and deutetrabenazine sold by Teva (Austedo) for the treatment of DT, and now unbranded TV ads and websites for TD abound as if the condition has just been discovered.

Like other unbranded marketing, TD ads and websites omit mention of any drug names but urge people to see their doctors and describe all their symptoms. Web sites even offer a “discussion guide” to make sure the physician prescribes the exact drug being marketed — co-opting the patient in the sales effort as most DTC marketing does. Ads also urge people not to stop the drug causing their TD.

Why object to a treatment for TD if it works? First of all, there is price.

Ingrezza would cost $752,080 and Austedo, $1,100,773 based on quality-adjusted year life (QALY) measures says Managed Care magazine. Industry price gouging has become so blatant that both sides of the congressional aisle are alarmed.

Novartis’s cancer drug, Kymriah, costs $475,000 per patient. Actimmune, a drug to boost the immune system in chronic granulomatous disease, costs $52,321.80 for one month, and the gallstone drug Chenodal costs $42,570 a month. We all know the price of Hep C drugs.

While industry claims the six and even seven-digit prices of new drugs it is rolling out reflect “research,” the prices are widely seen as opportunistic or even extortionary — an offer patients, clinicians, and insurers “can’t refuse.”

Secondly, add-on drugs are a shrewd strategy to double and triple-drug industry profits. Don’t stop your drug just because it doesn’t seem to be working or is causing uncomfortable side effects — add another drug or two has been the “polydrug” message for years. Don’t forget Seroquel, an aggressively prescribed SGA, is itself an add-on drug when antidepressants aren’t working.

Meanwhile, drugs that are sorely needed, such as antibiotics for carbapenem and vancomycin-resistant bacteria are conspicuously not developed because they are not profitable to industry — even when our tax dollars are handed to industry to develop them. How about an antifungal drug to treat candida auris, increasingly becoming a hospital scourge? No, the drug industry would rather seek Wall Street riches at the price of public health.

There are two more suggestions when it comes to the stigmatizing TD. Why can’t industry develop antipsychotic drugs that don’t cause it — or would that not be as profitable as an add-on expensive drug? And how about requiring informed consent forms from all the patients cavalierly put on SGAs for conditions like autism, bipolar disorder, ADHD, anxiety, and depression in which they acknowledge that they might be condemned to lifelong TD? That would likely reduce the number of TD sufferers.

Martha Rosenberg is a health reporter and the author of Born With a Junk Food Deficiency.  

ADVERTISEMENT

Image credit: Shutterstock.com 

Prev

The stethoscope is not just a prop

November 30, 2019 Kevin 1
…
Next

Doctors on TV: today vs. 20 years ago

November 30, 2019 Kevin 1
…

Tagged as: Medications, Neurology

Post navigation

< Previous Post
The stethoscope is not just a prop
Next Post >
Doctors on TV: today vs. 20 years ago

ADVERTISEMENT

More by Martha Rosenberg

  • Drug giants face suit over hidden cancer risks

    Martha Rosenberg
  • How drug companies profit by inventing diseases

    Martha Rosenberg
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg

Related Posts

  • Black boxes: health warning or profit warning?

    Martha Rosenberg
  • Is there a link between readmission and a hospital’s non-profit status?

    David Lozar, MD
  • How drugmakers became masters at producing authorized generics

    Jay Hancock and Sydney Lupkin
  • The obscene price of insulin: This is what happens when health care is for profit

    Therese Zink, MD, MPH
  • Cutting the red tape with buprenorphine treatment for opioid use disorder

    Christina Kinnevey, MD
  • The pandemic’s epidemic: opioid use disorder and subpar suboxone access   

    Jonathan Staloff, MD and Claire Simon, MD

More in Meds

  • Tofacitinib: a lesson in heart-immune health

    Larry Kaskel, MD
  • The case for regulating, not banning, kratom

    Heidi Sykora, DNP, RN
  • How India-Pakistan tensions could break America’s generic drug pipeline

    Adwait Chafale
  • The unfair war on buprenorphine

    Brian Lynch, MD
  • Drug giants face suit over hidden cancer risks

    Martha Rosenberg
  • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

    Adwait Chafale
  • Most Popular

  • Past Week

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • The mental health workforce is collapsing

      Ronke Lawal | Conditions
    • The measure of a doctor, the misery of a patient

      Anonymous | Physician
    • A doctor’s struggle with burnout and boundaries

      Humeira Badsha, MD | Physician
    • The stoic cure for modern anxiety

      Osmund Agbo, MD | Physician
    • Why more doctors are seeking therapy to sustain their careers and lives [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • The ignored clinical trials on statins and mortality

      Larry Kaskel, MD | Conditions
    • How one physician redesigned her practice to find joy in primary care again [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why doctors must fight for a just health care system

      Alankrita Olson, MD, MPH & Ashley Duhon, MD & Toby Terwilliger, MD | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
  • Recent Posts

    • Why more doctors are seeking therapy to sustain their careers and lives [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why a 500-calorie meal isn’t always fit

      Larry Kaskel, MD | Conditions
    • A doctor’s promise after a patient’s suicide

      Vikram Madireddy, MD | Physician
    • Building a practice and avoiding business pitfalls

      David B. Mandell, JD, MBA | Finance
    • The first week of an attending physician

      Sami Sinada, MD | Physician
    • How physician obesity affects patient care

      June Pomeroy, RN | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 3 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • The mental health workforce is collapsing

      Ronke Lawal | Conditions
    • The measure of a doctor, the misery of a patient

      Anonymous | Physician
    • A doctor’s struggle with burnout and boundaries

      Humeira Badsha, MD | Physician
    • The stoic cure for modern anxiety

      Osmund Agbo, MD | Physician
    • Why more doctors are seeking therapy to sustain their careers and lives [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • The ignored clinical trials on statins and mortality

      Larry Kaskel, MD | Conditions
    • How one physician redesigned her practice to find joy in primary care again [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why doctors must fight for a just health care system

      Alankrita Olson, MD, MPH & Ashley Duhon, MD & Toby Terwilliger, MD | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
  • Recent Posts

    • Why more doctors are seeking therapy to sustain their careers and lives [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why a 500-calorie meal isn’t always fit

      Larry Kaskel, MD | Conditions
    • A doctor’s promise after a patient’s suicide

      Vikram Madireddy, MD | Physician
    • Building a practice and avoiding business pitfalls

      David B. Mandell, JD, MBA | Finance
    • The first week of an attending physician

      Sami Sinada, MD | Physician
    • How physician obesity affects patient care

      June Pomeroy, RN | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Drugmakers discover tardive dyskinesia. And they profit in it.
3 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...